Skip to contentA
Amphastar Pharmaceuticals, Inc.
A
AMPHAmphastar Pharmaceuticals, Inc. Q4 2019 · 10-K
Revenue$83.38M$83.38M−7.0% vs Q4 2018 Net Income-$1.03M-$1.03MN/M vs Q4 2018 EPS Diluted-$0.02-$0.02N/M vs Q4 2018 Gross Profit$33,381,000−3.8% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Amphastar Pharmaceuticals, Inc. · CIK 1297184 · Engraved from SEC EDGAR
derived
Operating Cash Flowderived$5,652,000−40.6% Free Cash Flowderived-$2,758,000N/M Margins · derivedGross margin40.0%+1.4 pt vs Q4 2018
Operating margin-0.3%−2.0 pt vs Q4 2018
Net margin-1.2%−3.3 pt vs Q4 2018
ended Dec 31, 2019 · filed Mar 16, 2020 · 76 d after period end